Comparing TBT to Disorder-Specific Psychotherapy in Veterans With Social Anxiety Disorder
Cognitive behavioral therapy (CBT) is a brief, efficient, and effective treatment for individuals with depressive/anxiety disorders. However, CBT is largely underutilized within the Department of Veterans Affairs due to the cost and burden of trainings necessary to deliver all of the related disorder-specific treatment
| Condition(s) | Social Anxiety Disorder |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Cognitive behavioral therapy (CBT) is a brief, efficient, and effective treatment for individuals with depressive/anxiety disorders. However, CBT is largely underutilized within the Department of Veterans Affairs due to the cost and burden of trainings necessary to deliver all of the related disorder-specific treatments (DSTs). Transdiagnostic Behavior Therapy (TBT), in contrast, is specifically designed to address numerous distinct disorders within a single protocol in Veterans with depressive/anxiety disorders. The proposed research seeks to evaluate the efficacy of TBT by assessing psychiatric symptomatology and related impairment outcomes in Veterans with social anxiety disorder and comorbid posttraumatic stress via a randomized controlled trial of TBT and an existing DST. Assessments |
| Who can participate | Inclusion Criteria: * Participants must be Veterans and registered at Ralph H. Johnson Veterans Affairs Health Care System * Participants must be clearly competent to provide informed consent for research participation * Participants must meet DSM-5 criteria for social anxiety disorder * Participants must have clinically significant symptoms of comorbid posttraumatic stress Exclusion Criteria: * recent history (\< 2 months) of psychiatric hospitalization or a suicide attempt as documented in their medical record, * acute, severe illness or medical condition that likely will interfere with study procedures as documented in their medical record * recent start of new psychiatric medication(s) (\< 4 weeks), * primary diagnosis of a condition associated with psychotic symptoms, personality diso |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | VA Office of Research and Development |
| Locations | Charleston, South Carolina, United States |
| Start date | 2024-04-01 |
| NCT ID | NCT05858346 |
| Official listing | https://clinicaltrials.gov/study/NCT05858346 |